| Code | CSB-RA012887MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to TB-006, targeting LGALS3 (Galectin-3), a beta-galactoside-binding lectin that plays crucial roles in cell adhesion, proliferation, differentiation, and apoptosis. LGALS3 functions both intracellularly and extracellularly, mediating diverse processes including pre-mRNA splicing, cell cycle regulation, and immune responses. This protein is implicated in various pathological conditions, particularly in cancer progression where it promotes tumor cell invasion, metastasis, and angiogenesis. Elevated LGALS3 expression has been associated with poor prognosis in multiple malignancies, and it also serves as a biomarker in heart failure and fibrotic diseases.
TB-006 represents a therapeutic antibody that has been investigated for its potential to inhibit Galectin-3-mediated pathways in oncology and fibrosis research. This biosimilar antibody provides researchers with a valuable tool for investigating LGALS3 biology, exploring its role in tumor microenvironment modulation, studying immune cell regulation, and evaluating potential therapeutic interventions in cancer and fibrotic disorders.
There are currently no reviews for this product.